Abnormalities in GABA neurotransmission in the prefrontal cortex of schizophrenic subjects may reflect selective alterations in the axon terminals of chandelier cells, a specialized subclass of cortical GABA neurons.
Theories of the pathophysiology of schizophrenia have traditionally emphasized alterations in specific neurotransmitter systems. In addition to dopamine, and more recently glutamate, which have received the most press in this regard, a substantial body of evidence suggests that schizophrenia may be associated with alterations in GABA neurotransmission. In particular, dysfunction of the dorsolateral prefrontal cortex (DLPFC), which appears to contribute to certain cognitive symptoms of schizophrenia, may be related to changes in markers of the GABA system. For example, both the release 1 and uptake 2 of cortical GABA have been reported to be reduced in schizophrenia. In addition, the expression of the mRNA for glutamic acid decarboxylase, the synthetic enzyme for GABA, is decreased in the DLPFC of subjects with schizophrenia, 3 as is the activity of this enzyme. 1, 4 Finally, abnormalities in GABA A receptors in the DLPFC of schizophrenic subjects have been observed in ligand-binding studies. 5 However, understanding the pathophysiological significance of such changes in a neurotransmitter system requires an appreciation of how they affect the flow of information processing within the DLPFC and in the projections from the DLPFC to other brain regions. In other words, alterations in DLPFC GABA, or any other neurotransmitter system, must be considered within the context of the neural circuitry that it influences.
A circuitry-based interpretation of neurotransmitter abnormalities is clearly critical in the case of GABA, because GABA is expressed in at least a dozen different classes of local circuit neurons in the primate DLPFC (Figure 1) . 6 These GABA-containing neurons can be classified based upon their content of a specific calcium-binding protein and the synaptic targets of their axons. For example, the axon terminals of many GABA neurons that contain the calcium-binding protein calretinin target the dendritic shafts of both pyramidal and nonpyramidal neurons, and have other morphoCorrespondence: DA Lewis, MD, University of Pittsburgh, Departments of Psychiatry and Neuroscience, Pittsburgh, PA 15213, USA logical features of double bouquet neurons. In contrast, the calcium-binding protein parvalbumin appears to be expressed predominantly in the wide arbor (or basket) and chandelier subclasses of GABA neurons. In addition to differences in their somal morphology and laminar distribution, wide arbor and chandelier cells can be differentiated on the basis of the synaptic targets of their axons. The axon terminals of wide arbor cells synapse primarily on the cell body, dendrites and dendritic spines of pyramidal neurons, whereas the axon terminals of chandelier cells form synapses exclusively with the axon initial segment of pyramidal neurons. These observations indicate that subclasses of GABA neurons have different influences on pyramidal cells, the principal type of cortical excitatory neuron. Consequently, understanding the functional impact of alterations in GABA neurotransmission in schizophrenia depends upon which population(s) of GABA neurons are affected.
Interestingly, several features of chandelier cells (sonamed by Szentágothai 7 because the extensively arborizing axon of these neurons give rise to distinctive vertical arrangements of axon terminals thought to resemble candlesticks) suggest that they may have been preferentially involved in the pathophysiology of schizophrenia. First, since these neurons provide inhibitory synapses very close to the site of action potential generation in pyramidal cells, chandelier neurons are positioned to powerfully regulate the excitatory output of pyramidal neurons, and consequently to substantially affect patterns of neuronal activity both within the DLPFC and in the numerous brain regions that receive projections from the DLPFC. 8 Second, chandelier cells appear to be among the subpopulation of GABA neurons that receive direct synaptic input from dopamine axons, 9 suggesting that these neurons may mediate, at least in part, the effects of altered DLPFC dopamine function in schizophrenia. Finally, in immunocytochemical studies, antibodies against either parvalbumin or the GABA membrane transporter GAT-1 clearly reveal the distinctive axon terminals of chandelier cells. As shown in the Image Section and Figure 2 , the vertical alignment of these axon terminals forms characteristic arrangements (termed 'cartridges') that can easily be distinguished from other GABA terminals containing the same markers. Interestingly, the density of these axon cartridges in the DLPFC changes substantially during late adolescence, 10 the typical age of onset of schizophrenia. For these reasons, we recently evaluated the integrity of the axon terminals of chandelier cells in two regions (areas 9 and 46) of the DLPFC in subjects with schizophrenia. 11 In both regions, the density of GAT-1-labeled axon cartridges was decreased on average by 40% in subjects with schizophrenia compared to both normal controls and subjects with non-schizophrenic psychiatric disorders. In over 70% of the cases, cartridge density was decreased in the schizophrenic subject relative to both of the matched comparison subjects. In addition, the density of labeled cartridges did not differ between normal controls and subjects who had been treated with antipsychotic medications for other psychotic disorders.
These changes also appeared to be selective for the axon terminals of the chandelier class of GABA neurons. For example, the density of axon terminals immunoreactive for calretinin, a calcium-binding protein found in other types of GABA neurons, did not differ between schizophrenic and control subjects.
Although these findings are suggestive of a selective and disease-specific alteration in the axon terminals of the chandelier class of GABA neurons in schizophrenia, the exact nature of the change is not yet clear. The decreased density of labeled axon cartridges could be a consequence of a reduced number of chandelier neurons, but this explanation seems unlikely since the density of neurons containing parvalbumin, a calciumbinding protein present in chandelier neurons, was not altered in the DLPFC in the same schizophrenic subjects. 12 The decreased density of GAT-1-immunoreactive axon cartridges could also represent an actual reduction in the number of intact cartridges, or in the number of boutons per cartridge, such that some individual cartridges lose their distinctive morphology. Although this interpretation may be consistent with the results of other studies indicating that the number of axon terminals in the DLPFC is diminished in schizophrenia, 13, 14 it is not supported by our observation that the length of the labeled cartridges did not differ between schizophrenics and controls.
11 Alternatively, the decreased density of labeled cartridges might reflect reduced levels of GAT-1 protein in chandelier neuron axon terminals. Interestingly, during postnatal development, the detectability of other protein markers for chandelier axon cartridges declines substantially 10 without apparent loss of axon terminals 15 or change in the total number of inhibitory synapses. 16 Whether due to fewer axon cartridges or decreased GAT-1 levels per cartridge, these findings suggest that inhibition to the axon initial segment of pyramidal cells is selectively altered in the DLPFC of schizophrenic subjects. The extent to which these alterations in chandelier neurons actually illuminate our understanding of the pathophysiology of schizophrenia depends upon several factors. First, additional studies are required to determine how common this finding is among subjects with schizophrenia, and whether changes in chandelier neuron axon cartridges are preferentially associated with certain clinical features of the illness. Second, given that pyramidal cells in each cortical layer tend to be driven by different sources of excitatory inputs and to innervate different brain regions, it will be important to determine whether the axon cartridges in certain cortical layers are preferentially affected in schizophrenia. For example, a decrease in labeled axon cartridges in the middle cortical layers would be of interest in the context of recent studies suggesting that inputs from the medial dorsal thalamus, which terminate primarily in the middle cortical layers, are reduced in schizophrenia. 17 Finally, the identification of alterations in a specific subclass of GABA neurons and their related circuitry may reveal options for novel forms of therapeutic intervention. For example, characterization of the unique molecular features of chandelier cells, a goal that is now feasible given the availability of techniques for harvesting and analyzing RNA from single cells, may provide a venue for the design of therapeutic agents that are specifically targeted to adjust chandelier cell function.
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